Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.62 |
| ▸ | CTSK | P43235 | 3/20 | 0.62 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.51 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269453 | 1.00 | CTSS (0.62) | CTSSCTSKJAK3BTKPTPN1 | |
| SCHEMBL268271 | 0.87 | JAK3 (0.55) | CTSSCTSKJAK3BTKPTPN1 | |
| SCHEMBL270313 | 0.87 | JAK3 (0.48) | CTSSCTSKJAK3BTKPTPN1 | |
| SCHEMBL268958 | 0.87 | JAK3 (0.48) | CTSSCTSKJAK3BTKPTPN1 | |
| SCHEMBL25255205 | 0.86 | JAK3 (0.54) | CTSSCTSKJAK3BTKPTPN1 | |
| SCHEMBL25255207 | 0.86 | JAK3 (0.54) | CTSSCTSKJAK3BTKPTPN1 | |
| SCHEMBL269021 | 0.86 | JAK3 (0.47) | CTSSCTSKJAK3BTKPTPN1 | |
| SCHEMBL269284 | 0.86 | JAK3 (0.47) | CTSSCTSKJAK3BTKPTPN1 | |
| SCHEMBL30714043 | 0.85 | JAK3 (0.52) | CTSSCTSKJAK3BTKPTPN1 | |
| SCHEMBL29194093 | 0.85 | JAK3 (0.52) | CTSSCTSKJAK3BTKPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
| EP-1912946-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | Eli Lilly and Company (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015767-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | CTSS 177/4885CTSK 286/4885JAK3 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.